Increased *Akkermansia* abundance is associated with increased colonic mucosal ω-3 fatty acids and decreased colonic mucosal PGE₂ concentrations following healthy dietary pattern interventions

S.B. Rifkin¹, A. Sen², D.K. Turgeon¹, R. Chan²,³, M.T. Ruffin⁴, D.E. Brenner¹, P.D. Schloss⁵, Z. Djuric²

1. Michigan Medicine Department of Internal Medicine, Ann Arbor, 48109, USA.
2. Michigan Medicine Department of Family Medicine, Ann Arbor, 48109, USA.
3. Present address: 10X Genomics, San Francisco, CA 94111
4. Penn State Cancer Institute, Hershey, PA, 17033, USA.
5. Michigan Medicine Department of Immunology and Microbiology, Ann Arbor, MI, 48109, USA

Corresponding author:
Samara B Rifkin, MD, ScM
Division of Gastroenterology and Hepatology
University of Michigan School of Medicine
srifkin@med.umich.edu

Short title: colonic ω-3 fatty acids and *Akkermansia*

Keywords: ω-3 polyunsaturated fatty acids (ω-3 PUFA), prostaglandin E₂ (PGE₂), cyclooxygenase (COX) -1 and COX-2, *Akkermansia*
ABSTRACT

Both increased dietary intake of ω-3 polyunsaturated fatty acids (PUFA) and subsequent increases in colonic mucosal ω-3 PUFA concentrations have been linked to improved gut barrier function and decreased risks of metabolic diseases and cancer. In addition, increased dietary ω-3 PUFA has been linked to eubiosis in mouse studies. Increased ω-3 PUFA function in part to reduce cyclooxygenase-(COX) mediated prostaglandin E2 (PGE2) production, a biomarker of cancer risk linked to compromised gut barrier function. We analyzed data from a dietary intervention study in individuals at increased risk of colon cancer to determine whether changes in the mucosal microbiome composition were associated with changes in colonic mucosal ω-3/ω-6 PUFA ratio. Microbiome analyses of colonic biopsies before and after the dietary intervention from 86 participants were done by sequencing the V4 region of the 16S rRNA gene. Multivariable linear regression models were used to evaluate further whether changes in Akkermansia was associated with changes in each colonic tissue variable: ω-3/ω-6 PUFA ratios, PGE2 concentrations, and expression of COX-1 and COX-2. The median dietary intake and mucosal ω-3/ω-6 PUFA ratio increased after intervention. Greater increases in mucosal ω-3/ω-6 PUFA ratios after intervention were significantly associated with several changes in taxon abundance, including increased Akkermansia muciniphilia relative abundance. An increased abundance of Akkermansia muciniphilia also was associated significantly with decreased PGE2 concentrations but not with changes in COX expression. Further studies are warranted to elucidate mechanisms by which Akkermansia may affect or is affected by these pathways and the relative importance of individual dietary components.
Introduction

Chronic low grade inflammation has been implicated in the rising prevalence of chronic diseases including obesity, diabetes, cardiovascular diseases and cancer.¹,² It has been suggested that Western diets containing relatively high saturated fatty acids and ω-6 polyunsaturated fatty acids (PUFA) but low monounsaturated fatty acids (MUFA) and ω-3 PUFA contribute to pro-inflammatory states and the rising prevalence of chronic diseases.³ In particular, consumption of ω-3 PUFA from fish and other foods results in a more favorable eicosanoid profile to reverse the chronic inflammation associated with reduced risks of obesity, diabetes and cancer.⁴–⁶ Dietary fats, however, have multi-faceted effects on inflammation and chronic diseases that also appears to include changes in the microbiome and gut barrier function.²

High saturated fat diets have been shown to compromise gut barrier function through mucus thinning and loss of junction barrier proteins leading to metabolic endotoxemia.²,⁷,⁸ Systemic exposures to bacterial lipopolysaccharides (LPS) are thought to mediate this process. LPS, a major component of the gram negative bacterial outer membrane, can be absorbed into the bloodstream to stimulate toll like receptor 4 (TLR4) with reactive elevations in serum pro-inflammatory eicosanoids and cytokines.²,⁸,⁹ Conversely, certain anti-inflammatory dietary components, including ω-3 PUFA, have been shown to prevent or reverse metabolic endotoxemia and chronic low grade inflammation by improving gut barrier function.²,⁸,¹⁰

Dietary ω-3 PUFA affect gut barrier function by several mechanisms. The ω-3 PUFA inhibit formation of pro-inflammatory eicosanoids such as prostaglandin E₂ (PGE₂) from the cyclooxygenase (COX-1) and COX-2-mediated oxidation of arachidonic acid (AA), and the reduction in PGE₂ signaling reduces local inflammatory reactions to maintain normal barrier function.¹¹ The ω-3 PUFA compete with AA as substrates for COX-1 and COX-2 enzymes and eicosapentaenoic acid ω-3 (EPA) also binds to COX-1 to allosterically inhibit AA oxygenation.¹² In addition, ω-3 PUFA may prevent inflammation by influencing microbiome composition.¹³ A preponderance of studies have found that ω-3 PUFA administration increases LPS-suppressing bacteria including Akkermansia muciniphila.²,¹⁰,¹⁴–¹⁹ Increased tissue ω-3 PUFA in a transgenic mouse model that endogenously produces ω-3 PUFA led to lower levels of LPS-producing bacteria and higher levels of LPS-suppressing bacteria versus that in wild type mice.¹⁰,¹⁴ In human studies, the presence of A. muciniphila in the outer mucus layer of the colon was associated with reduction of metabolic endotoxemia and chronic low-grade inflammation brought on by high fat diet and obesity. These beneficial effects were attributed to the role of A. muciniphila in maintaining gut barrier function.¹⁶
Most studies aimed at investigating the relationship between PUFAs and intestinal microbiome composition have quantified the intestinal microbiota in excreted stool and measured PUFAs in the serum. Excreted stool, however, does not reflect the bacterial milieu adhering to the colonic mucosal surface. Bacteria adhering to the colonic mucin are in close proximity to the colon epithelial cells. Therefore, characterizing the bacteria associated with the colonic mucosa may be more meaningful to evaluate in the interaction between the diet and the gut microbiome. In the present study, we performed a secondary analysis of a study that recruited individuals with an elevated risk of colorectal cancer and randomized them to either a Healthy Eating diet or a Mediterranean diet. Both diet arms achieved similar increases in median dietary and median colonic mucosal $\omega-3/\omega-6$ PUFA ratios, but there was substantial inter-individual variability in fatty acid changes within each arm. This afforded the opportunity to evaluate whether changes in the colonic mucosal microbiome were associated with changes in colonic mucosal $\omega-3/\omega-6$ PUFA ratios. Because of its known role in promoting colonic integrity and limiting metabolic endotoxemia, we investigated further whether *Akkermansia* abundance was associated with colonic mucosal $\omega-3/\omega-6$ PUFA ratio as well as colonic mucosal COX-1 and 2 gene expression and PGE₂ using multivariable linear regression models.

**Methods**

**The Healthy Eating Study**

Methods for conducting the Healthy Eating Study have been previously published. This study was conducted according to the Declaration of Helsinki and all procedures involving human subjects were approved by The University of Michigan Institutional Review Board (HUM00007622). This study was registered at ClinicalTrials.gov (registration no. NCT00475722). In brief, 120 persons at increased risk of colorectal cancer were enrolled from Ann Arbor, MI, and surrounding areas from July 2007 to November 2010. Increased risk was defined as having a family history of colorectal cancer in either one first-degree relative or two second-degree relatives, or having a personal history of colorectal adenoma or cancer. All study participants provided informed, signed consent prior to randomization.

A total of 94 participants completed 6 months of study. Participants underwent un-prepped flexible sigmoidoscopy before and after the 6-month intervention. Eight colorectal biopsy samples were obtained from the colon, 20 to 25 cm from the anal sphincter. Biopsy samples were flash frozen in liquid nitrogen within 5 seconds and kept at −70°C until analysis. Colon biopsy samples were available for microbiome analysis from 94 participants at baseline and from 86 participants after dietary...
intervention. Blood was collected after an overnight fast and prepared serum was kept frozen at -80 °C until analysis.

Measures of fatty acids, prostaglandin E$_2$, COX-1 and COX-2

Serum and colon biopsy samples were analyzed for complete fatty acid profiles as methyl esters using gas chromatography—mass spectroscopy (GC-MS). ω-3 PUFA was calculated by summing 18:3, 20:5, and 22:6, whereas ω-6 PUFA was calculated by summing 18:2 (n6), 20:3 (n6), 20:4 (n6). The ratio was then produced dividing ω-3 PUFA by ω-6 PUFA. PGE$_2$ in colon mucosal biopsy samples was analyzed using liquid chromatography with mass spectrometry as previously described. COX-1 and COX-2 gene expression was quantified by Quantitative real-time PCR.

Dietary intervention

Participants were randomized to receive dietary counseling to follow either a Healthy Eating diet or a Mediterranean diet and the specific details of the two dietary interventions have been published previously. Overall, the change in dietary ω-3/ω-6 PUFA ratios and colonic mucosal ω-3/ω-6 PUFA ratios were similar between the two study arms, however there was inter-individual variation in fatty acid intakes and colonic tissue levels across the entire study population that allowed us to perform this secondary data analysis.

Dietary data was obtained at baseline and 6 months using two 24-hour recalls and two days of written food records (four non-consecutive days per time point). The analysis of food records and recalls were performed with the Nutrition Data System for Research (2013 version; University of Minnesota, Nutrition Coordinating Center). Food and nutrient intakes were averaged over the four days of intake for each subject at each time point.

Mucosal microbiome 16S rRNA sequencing and processing

DNA was isolated from biopsy samples using PowerMag Microbiome RNA/DNA Isolation Kit (Mo Bio Laboratories, Inc) and epMotion 5075 liquid handling system (Eppendorf). The hypervariable V4 region was amplified using primers described previously and 16S rRNA gene sequences were processed using the mothur software package. FASTQ files were generated for paired end reads. Paired-end reads were merged into contigs, aligned to the SILVA 16S rRNA sequence database (version 138), and low quality sequences and chimeras were removed. Sequences were classified by training a naive Bayesian classifier with a 16S rRNA gene training set (Ribosomal Database Project (RDP)). Sequences were then clustered into operational taxonomic units (OTUs) using a 97 % similarity cutoff with the OptiClust
clustering algorithm.\textsuperscript{26} Samples were rarefied to 1,047 sequences per sample, which eliminated ten of 179 samples.

**Statistical analysis**

Individuals were categorized according to baseline colonic mucosal $\omega-3/\omega-6$ PUFA ratios tertiles. Baseline characteristics variables were tested for normality using the Shapiro-Wilk’s method in R (version 4.0.2), which did not follow a normal distribution. Therefore, these values were assessed using medians and interquartile ranges for continuous variables, and as frequencies and percentages for categorical variables. Additionally, fatty acid dietary intake, serum and colonic mucosal concentrations before and after dietary intervention did not follow a normal distribution. We therefore calculated median differences in these variables before and after intervention. Statistically significant changes in median differences in nutrient variables were assessed using Wilcoxon signed rank test.

We characterized variation in microbial community using metrics for 1) $\alpha$ diversity (Shannon index) to quantify intraindividual variation and 2) $\beta$-diversity-based distance metric (Bray-Curtis) to quantify the distance between individuals. These values were calculated using mothur software package. We compared Shannon index across serum, diet and colonic mucosal $\omega-3/\omega-6$ PUFA ratios tertiles using Kruskal-Wallis. Associations between microbiome variation and serum, diet and colonic mucosal $\omega-3/\omega-6$ PUFA ratios were assessed via permutational multivariate analysis of variance (PERMANOVA) both as continuous variables and using variables categorized into tertiles. To visualize the Bray-Curtis distance values between samples, Non-metric multidimensional scaling-NMDS was calculated and results were plotted using the vegan package within the R program.

Linear regression was used to identify bacterial taxa whose relative abundance were associated with changes in of serum, diet and colonic mucosal $\omega-3/\omega-6$ PUFA ratios. The Benjamini–Hochberg (B-H) method was used to adjust P values in the multiple correlation analyses while controlling for the expected false discovery rate at 0.05. We then constructed a multivariable linear regression models for each colonic mucosal variable ($\omega-3/\omega-6$ PUFA ratio, PGE\textsubscript{2} levels, COX-1 and COX-2 gene expression) to assess if a given colonic mucosal variable was associated with Akkermansia abundance. We modeled each colonic mucosal variable ($\omega-3/\omega-6$ PUFA ratio, PGE\textsubscript{2} levels, COX-1 and COX-2 gene expression) at 6 months as a factor of log change in Akkermansia abundance levels after intervention, also adjusting for the colonic mucosal variable at baseline and age, sex and body mass index (BMI).

**Results**
Baseline characteristics of study participants

The 86 study participants with sequenced biopsy samples available at one or both time points were 74% female, had a median age of 54 years, and a median BMI of 27 kg/m². A small proportion of participants (18%) were taking nonsteroidal anti-inflammatory drugs (NSAIDs). Baseline data are shown by tertiles of colonic mucosal ω-3/ω-6 PUFA ratios (Table 1). Age, BMI, sex, NSAID use, and PGE₂ were not different across tertiles of colonic mucosal ω-3/ω-6 PUFA ratios.

Effects of dietary intervention on fatty acid intake and concentrations

Median differences in fatty acid intake, serum and colonic mucosal concentrations after each dietary intervention are shown in Table 2. Dietary ω-3 PUFA increased in the Healthy Eating arm (P=0.04), while dietary ω-6 PUFA decreased in the Mediterranean arm (P<0.0001). The dietary ω-3/ω-6 PUFA ratio increased in both the Healthy Eating arm (P=0.01) and the Mediterranean arm (P=0.0002). Serum ω-3 PUFA increased in the Healthy Eating arm (P=0.004) and serum ω-6 PUFA decreased in the Mediterranean arm (P=0.04). The median serum ω-3/ω-6 PUFA ratio remained the same in the Healthy Eating arm and increased from 0.09 to 0.12 in the Mediterranean arm (P=0.03). Median colonic mucosal PGE₂ concentrations did not change appreciably in the Healthy Eating arm (P=0.8) nor the Mediterranean arm after 6 months of intervention (P=0.7). The colonic mucosal ω-3/ω-6 PUFA ratio increased in both the Healthy Eating arm (P=0.03) and the Mediterranean arm (P=0.001). We confirmed that both arms achieved similar changes in colonic mucosal ω-3/ω-6 PUFA ratio. However, there was substantial inter-individual variation in colonic mucosal concentrations of all these analytes.

Effects of fatty acid concentrations on gut microbiota

To test the hypothesis that fatty acids can influence the microbiome, we examined how global microbiome features, including within community variation (alpha diversity with Shannon index) and between community variation (beta diversity using Bray-Curtis distance), varied according to colonic mucosal, serum and dietary fatty acid levels. The Shannon index was inversely associated with baseline colonic mucosal ω-3/ω-6 PUFA (P=0.02), but not associated with serum ω-3/ω-6 PUFA ratio at baseline nor any of these variables at 6 months after intervention (Figure 1).

When we performed PERMANOVA analysis, we found no differences in beta diversity or community distance according to diet (P= 0.5), or colonic mucosal ω-3/ω-6 PUFA ratio at 6 months (P= 0.1), however serum ω-3/ω-6 PUFA ratio at 6 months showed a stronger association with beta diversity (P=0.003). We also performed PERMANOVA analysis using dietary (P=1.00), serum (P=0.09) and colonic mucosal ω-3/ω-6 PUFA ratio (P= 0.46) categorized into tertiles and found no differences in beta
diversity (see Figure 2). We found that when we performed pairwise PERMANOVA on serum \( \omega-3/\omega-6 \) PUFA ratio levels tertiles at 6 months that none of the differences were significant (P=0.5).

Abundance of taxa by colonic mucosal, serum and dietary \( \omega-3/\omega-6 \) PUFA ratios at baseline

We identified several differentially abundant genera that were positively associated with baseline colonic mucosal \( \omega-3/\omega-6 \) PUFA ratio including *Varibaculum, Rhizobium, Porphyromonas, Mogibacterium, Megamonas, Coprobacillus, Butyricoccus, Actinomyces* and unclassified members of *Erysipelotrichaceae*. Unclassified members of *Lachnospiracea* were negatively associated with \( \omega-3/\omega-6 \) PUFA ratio (Figure 3).

The following genera were positively associated with baseline serum \( \omega-3/\omega-6 \) PUFA ratio (Figure 3): *Rothia, Phyllobacterium, Negativicoccus, Leuconostoc, Hydrogenoanaerobacterium, Enterococcus, Clostridium sensu stricto, Cloacibacterium, Brochothrix* and unclassified members of *Proteobacteria* and *Actinobacteria*. *Rothia, Phyllobacterium, Enterococcus, Coprobacillus, Butyricoccus, Brochothrix, Anaerotruncus* and unclassified member of *Actinobacteria* were positively associated with dietary \( \omega-3/\omega-6 \) PUFA ratio levels.

Abundance of taxa by colonic mucosal, serum and dietary \( \omega-3/\omega-6 \) PUFA ratios after 6 months

We identified several differentially abundant genera whose relative abundance were positively associated with colonic mucosal \( \omega-3/\omega-6 \) PUFA ratio including unclassified members of *Alphaproteobacteria*, *Clostridia* and *Lachnospiracea*, and *Akkermansia* at 6 months. *Odoribacter* was negatively associated with colonic mucosal \( \omega-3/\omega-6 \) PUFA ratio at 6 months (Figure 3).

The following genera were positively associated with serum \( \omega-3/\omega-6 \) PUFA ratio (Figure 3): *Varibaculum, Acinetobacter, Arcanobacterium, Stentotrophomonas, Streptococcus, Actinobaculum, Actinomyces, Subdoligranulum*, and unclassified members of *Betaproteobacteria*, while *Blautia, Dorea* and *Bifidobacterium* were negatively associated at 6 months. *Veillonella, Streptococcus, Butyricoccus, Helcococcus* and unclassified members of *Clostridiales* were positively associated with dietary \( \omega-3/\omega-6 \) PUFA ratio levels.

*Akkermansia* abundance and colonic mucosal \( \omega-3/\omega-6 \) PUFA ratio, COX gene expression, PGE\( _2 \) concentration

We further investigated whether *Akkermansia* abundance was associated with colonic mucosal \( \omega-3/\omega-6 \) PUFA ratio as well as colonic mucosal COX-1 and 2 gene expression, PGE\( _2 \) levels adjusting for age,
BMI, sex and dietary ω-3/ω-6 PUFA ratio intake. COX-1 and COX-2 were not associated with ω-3/ω-6 PUFA ratio. We investigated whether these colonic mucosal nutrient concentrations, gene expression and metabolite concentrations were associated with levels of _Akkermansia_ abundance using two different linear models.

To assess the effect of change in _Akkermansia_ abundance on colonic mucosal ω-3/ω-6 PUFA ratio, PGE₂, COX-1 and COX-2 gene expression following the dietary intervention, we modeled each colonic mucosal variable at 6 months as the dependent variable adjusting for each colonic mucosal variable at baseline and change in _Akkermansia_ abundance using linear regression (Table 3). We found that a positive log change in _Akkermansia_ following the dietary intervention was significantly associated with increased colonic mucosal ω-3/ω-6 PUFA ratios at 6 months after adjusting for age, sex, BMI, and dietary ω-3/ω-6 PUFA ratios (P=0.02). When we modeled colonic mucosal PGE₂ at 6 months with adjustment for baseline values, a negative log change in _Akkermansia_ following the intervention conversely was associated with a positive change in colonic mucosal PGE₂ (P=0.01). COX-1 or COX-2 expression at 6 months were not associated with log change in _Akkermansia_ abundance (P=0.3) and (P=0.5), respectively.

**Discussion**

The two dietary intervention arms resulted in similar changes in serum and colonic mucosal ω-3/ω-6 PUFA ratios (Table 2). We therefore analyzed changes in colonic mucosal measures and in bacterial populations in all 86 study participants combined. The colonic mucosal ω-3/ω-6 PUFA ratio increased in the combined study population. Overall, we found that differences in PUFA incorporated in colonic tissues were not associated with global changes in the microbiome, but they were associated with specific microbiome changes. Alpha diversity, i.e. within community diversity, was associated with colonic mucosal ω-3/ω-6 PUFA ratios at baseline, but otherwise not associated with dietary or serum ω-3/ω-6 PUFA ratio at baseline or any nutrient ratios at 6 months (Figure 1). Beta diversity, i.e. inter-sample diversity, varied according to serum but not colonic mucosal ω-3/ω-6 PUFA concentration at 6 months (Figure 2). Our results analyzing differential taxon abundance associated with changes in ω-3/ω-6 PUFA ratio are consistent with both mouse studies and clinical interventions, which also found that higher ω-3 PUFA levels may influence the abundance of short chain fatty acid (SCFA) producing bacteria.

Several studies involving ω-3 supplementation reported increases in SCFA-producing bacteria. We also found a positive association between _Lachnospiracea_ and colonic mucosal ω-3/ω-6 PUFA ratios, but an inverse association with _Odoribacter_, both producers of SCFA (Figure 3).
In subsequent analyses, we focused on the association between *Akkermansia* abundance and colonic mucosal ω-3/ω-6 PUFA ratio concentrations that had emerged in taxon-wide analyses since a lot of information is available on the role of *Akkermansia muciniphila* in colon health. In addition to colonic mucosal PUFA, we explored the association between *Akkermansia* abundance and PGE$_2$, a pro-inflammatory mediator in the colon. PGE$_2$ is produced from COX-mediated oxygenation of arachidonic acid, an ω-6 PUFA. We found that increased abundance of the *A. muciniphila* after 6 months of dietary intervention was significantly and independently associated with increased colonic mucosal ω-3/ω-6 PUFA ratios and with decreased PGE$_2$ concentrations using two different types of linear models, adjusting for age, sex and BMI. This did not appear to be due to changes in COX-1 or COX-2 expression in colonic biopsy tissues.

*A. muciniphila* is found within the mucin layer and therefore is likely to impact the gut barrier function. Higher levels of *Akkermansia* abundance have been linked to decreased serum LPS levels, improved insulin resistance and low grade chronic inflammation. While obesity and high fat diets were associated with decreased levels of *Akkermansia* abundance, *Akkermansia* supplementation improved metabolic endotoxemia, hyperglycemia, and adiposity in mice fed a high fat diet. Additionally, *Akkermansia* is enriched in people who consume other diets that are known to enhance barrier function and improve metabolic endotoxemia, including general anti-inflammatory dietary patterns and functional foods rich in polyphenols including extracts of black raspberry, concord grape and cranberry.

Our findings of increased *Akkermansia* levels with higher colonic tissue ω-3/ω-6 PUFA ratios are compatible with prior animal studies and clinical interventions. Several murine models have also demonstrated that fish oil supplementation resulting in increased colonic mucosal ω-3/ω-6 ratios led to higher *Akkermansia* abundance levels, among other taxon. The association between *Akkermansia* and two variables in the same pathway in the expected directions makes a stronger argument for a causal relationship, however we did not find an association between increased ω-3/ω-6 PUFA ratios and decreased PGE$_2$ concentrations following the dietary intervention. Furthermore, the association between PGE$_2$ and *Akkermansia* abundance was not weakened when ω-3/ω-6 PUFA ratio was included in the model.

While there is accumulating evidence that colonic ω-3 PUFA may modify the colonic milieu and encourage the growth of *Akkermansia*, it is unclear how *Akkermansia* abundance may be influencing colonic mucosal PGE$_2$ levels or vice versa. A relevant mouse study demonstrated that increased SCFA levels promoted an increased PGE$_i$/PGE$_2$ ratio that in turn stimulated myofibroblast to express MUC-2,
an important component of barrier integrity. Conversely, another mouse study found that increased PGE$_2$ through its receptor EP4 reduced SCFA-producing bacteria leading to repression of intestinal Treg accumulation and accumulation of intestinal inflammation. While we speculate that colonic mucosal PUFA may influence the mucosal adherent microbiome, but the reverse or both directions could be true. Furthermore, we hypothesize that *Akkermansia* abundance may lead to improved gut barrier function and limit PGE$_2$ production, but the reverse could be true. Therefore, the direction of the proposed effect cannot be determined from a statistical model and should also be interpreted with caution.

Both increased ω-3 PUFA and *A. muciniphilia* may alleviate the pathogenesis of obesity and high saturated fat diet on chronic low grade inflammation by limiting metabolic endotoxemia and strengthening gut barrier function. In transgenic fat-1 mice that endogenously convert ω-6 PUFA to ω-3 PUFA, transgenic fat-1 mice harbored lower levels of LPS producing bacteria and higher levels of LPS-suppressing bacteria (*Bifidobacterium, A. muciniphilia*) as compared with wild type mice. These mice also demonstrated increased expression of intestinal alkaline phosphatase (IAP), an anti-inflammatory enzyme located on the brush border that protects against pathogenic bacteria. Notably IAP promotes anti-inflammatory effects on the GI mucosa by dephosphorylating microbial LPS and microbiota-produced ATP, an important inflammatory mediator. IAP has also been linked to improved gut barrier function and has been shown to alleviate metabolic disease. The authors hypothesized that increased tissue ratio of ω-3/ω-6 PUFA ratios led to increased expression of IAP which cultivated an intestinal milieu favoring growth of LPS-suppressing bacteria.

One strength of this study is the availability of colonic tissue for the fatty acid measures. Few studies have assessed the effect of colonic mucosal ω-3 PUFA on microbiome, and most studies have relied on self-reported diet, serum or RBC concentrations of ω-3 PUFA. Fatty acids are absorbed efficiently by the proximal small intestine with little residual traveling to the colon to affect the luminal microbiome composition. Therefore, the PUFA composition of colonic tissue more likely influences microbiome composition via indirect effects on the nature of the colonic barrier. The beneficial effects of colonic mucosal ω-3 PUFA have been shown to be manifested in part due to improved gut barrier function in both animal models and human intervention studies. In addition, our study also sequenced the microbiome adhering to colonic mucosal biopsies. Colonic mucosal fatty acids are more likely to affect bacteria associated with the mucosa, such as *A. muciniphilia*, a bacterium known to reside in the mucin in close proximity to the mucosa.
There are also several limitations to this study that should be recognized. The data in this study was analyzed using 16S rRNA and therefore our ability to determine changes in microbial function is limited. In addition, 16S rRNA analysis only allows resolution to the genus level. However, *A. muciniphilia* is the only bacterium of its genus known to colonize humans and therefore misclassification for this finding is unlikely. Lastly, sample size limited our ability to adjust for multiple covariates simultaneously.

In summary, we report a positive association between mucosal *Akkermansia* abundance and colonic tissue ω-3/ω-6 PUFA ratios and a negative association with colonic PGE₂ concentrations in subjects who had undergone dietary intervention, either Mediterranean or Healthy Eating, both of which resulted in similar dietary changes with the exception of monounsaturated fats. These results are consistent with animal models and human studies that provide accumulating evidence of a connection between ω-3 PUFA and increased *Akkermansia* abundance on gut barrier function. Our growing understanding of how both ω-3 PUFA and *Akkermansia* improve gut barrier function and potentially limit metabolic endotoxemia is compelling as a causal association between diet, microbiome and chronic low-grade inflammation. Future studies exploring the effect of colonic mucosal ω-3/ω-6 PUFA ratios on the microbiome, on *A. muciniphilia* in particular, and gut barrier function are warranted.
Acknowledgements

We thank all the individuals who volunteered to participate in the Healthy Eating Study. We acknowledge the contributions of Maria Cornellier in conducting the dietary counseling, Mary Rapai for study recruitment and coordination, Dr. Elkhansa Sidahmed for carrying out the gene expression analyses, Faith Umoh for carrying out the assays for LBP, and Jianwei Ren for the analyses of fatty acids, carotenoids and eicosanoids.

Financial Support

We acknowledge support from the University of Michigan Medical School Host Microbiome Initiative and NIH grants RO1 CA120381, Cancer Center Support Grant P30 CA046592, and the Rose and Lawrence C. Page, Sr. Family Charitable Foundation (to Dr. D. Kim Turgeon). Rena Chan was supported by the Cancer Biology Training Program grant T32 CA009676. The research used core resources supported by a Clinical Translational Science Award, NIH grant UL1RR024986 (the Michigan Clinical Research Unit), by the Michigan Diabetes Research Center, NIH grant 5P60 DK20572 (Chemistry Laboratory), the Michigan Nutrition and Obesity Research Center, and NIH grant P30 DK089503.

Conflict of Interest

The authors have no financial, professional or personal conflicts of interest to disclose.

Authors' contributions:

SR wrote the paper, analyzed data had primary responsibility for the final content. AS designed the research and analyzed data. RC performed data management and statistical analysis. MTR, DB and DKT designed the research. PDS analyzed data and wrote the paper. ZD designed the research, obtained the funding, and wrote the paper.
References


37. Willemsen LEM, Koetsier MA, van Deventer SJH, van Tol E a. F. Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. *Gut*. 2003;52(10):1442-1447. doi:10.1136/gut.52.10.1442


Table 1. Baseline characteristics of Healthy Dietary Study participants by tertiles of colonic mucosal ω-3/ω-6 PUFA (polyunsaturated fatty acids) ratios at baseline

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Tertile 1, N = 28</th>
<th>Tertile 2, N = 29</th>
<th>Tertile 3, N = 31</th>
<th>p-value&lt;sup&gt;c&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>ω-3/ω-6 PUFA ratio tertiles</td>
<td>&lt;0.07</td>
<td>0.07-0.27</td>
<td>&gt;0.27</td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>54 (48, 59)</td>
<td>53 (49, 57)</td>
<td>56 (48, 62)</td>
<td>0.79</td>
</tr>
<tr>
<td>Body Mass Index (kg/m²)</td>
<td>26.1 (23.1, 29.5)</td>
<td>27.2 (23.4, 32.0)</td>
<td>26.9 (23.2, 28.8)</td>
<td>0.32</td>
</tr>
<tr>
<td>Female</td>
<td>21 (75%)</td>
<td>22 (76%)</td>
<td>22 (71%)</td>
<td>0.94</td>
</tr>
<tr>
<td>Nonsteroidal anti-inflammatory drug (NSAID) use</td>
<td>5 (18%)</td>
<td>8 (28%)</td>
<td>3 (9.7%)</td>
<td>0.14</td>
</tr>
<tr>
<td>Lipopolysaccharide (LPS) binding protein (µg/ml serum)</td>
<td>15 (12, 24)</td>
<td>15 (12, 19)</td>
<td>15 (11, 21)</td>
<td>0.91</td>
</tr>
<tr>
<td>Prostaglandin E₂ (colon, pg/mg protein)</td>
<td>16 (10, 26)</td>
<td>12 (4, 23)</td>
<td>14 (7, 24)</td>
<td>0.38</td>
</tr>
<tr>
<td>Shannon Index</td>
<td>2.52 (2.39, 2.63)</td>
<td>2.48 (2.37, 2.55)</td>
<td>2.33 (2.02, 2.52)</td>
<td>0.03</td>
</tr>
<tr>
<td>Serum ω-3 PUFA&lt;sup&gt;+&lt;/sup&gt; (%)</td>
<td>3.16 (2.67, 3.62)</td>
<td>3.38 (2.77, 3.73)</td>
<td>4.33 (3.50, 5.33)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Serum ω-6 PUFA&lt;sup&gt;+&lt;/sup&gt; (%)</td>
<td>37 (35, 43)</td>
<td>36 (33, 43)</td>
<td>38 (33, 43)</td>
<td>0.62</td>
</tr>
<tr>
<td>Serum ω-3/ω-6 PUFA ratio</td>
<td>0.08 (0.07, 0.10)</td>
<td>0.09 (0.08, 0.10)</td>
<td>0.11 (0.09, 0.14)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Dietary ω-3 PUFA (g/day)</td>
<td>0.75 (0.58, 0.87)</td>
<td>0.74 (0.56, 1.04)</td>
<td>0.79 (0.56, 1.02)</td>
<td>0.88</td>
</tr>
<tr>
<td>Dietary ω-6 PUFA (g/day)</td>
<td>6.94 (5.97, 8.14)</td>
<td>6.75 (5.87, 8.38)</td>
<td>6.20 (5.44, 7.47)</td>
<td>0.32</td>
</tr>
<tr>
<td>Dietary ω-3/ω-6 PUFA ratio</td>
<td>0.11 (0.09, 0.13)</td>
<td>0.11 (0.10, 0.14)</td>
<td>0.13 (0.10, 0.16)</td>
<td>0.24</td>
</tr>
<tr>
<td>Colon tissue Saturated fatty acids&lt;sup&gt;c&lt;/sup&gt; (%)</td>
<td>32.1 (27.0, 34.8)</td>
<td>32.6 (31.4, 35.3)</td>
<td>32.6 (31.3, 33.1)</td>
<td>0.21</td>
</tr>
<tr>
<td>Colon tissue Monounsaturated fatty acids&lt;sup&gt;c&lt;/sup&gt; (%)</td>
<td>31.4 (28.1, 36.1)</td>
<td>32.2 (28.7, 33.9)</td>
<td>31.6 (29.1, 32.5)</td>
<td>0.91</td>
</tr>
</tbody>
</table>

<sup>1</sup> Summary statistics are presented as median (IQR); n (%). The statistical tests performed were the Kruskal-Wallis test or the chi-square test of independence for categorical variables.

<sup>2</sup> Fatty acids in serum and colon tissue are shown as percent of total fatty acids analyzed.
Table 2. Changes in dietary, serum and colonic mucosal fatty acid content before and after intervention in the Healthy Eating Study by diet arm assignment.

<table>
<thead>
<tr>
<th>Fatty acid %</th>
<th>Healthy Eating (n = 42)</th>
<th>Mediterranean (n = 44)</th>
<th>Total (n = 86)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median change(^1) (95 CI(^2))</td>
<td>Median change(^1) (95 CI(^2))</td>
<td>Median change(^1) (95 CI(^2))</td>
</tr>
<tr>
<td>MUFA(^3) (% (tissue)</td>
<td>0.67 (-0.44, 1.63)</td>
<td>0.36 (-1.10, 1.55)</td>
<td>0.50 (-0.34, 1.25)</td>
</tr>
<tr>
<td>MUFA(^3) (% (serum)</td>
<td>0.40 (-0.86, 1.52)</td>
<td>1.77 (0.60, 3.13)</td>
<td>1.06 (0.21, 1.91)</td>
</tr>
<tr>
<td>ω-6 PUFA(^4) (%) (tissue)</td>
<td>-0.17 (-1.37, 0.88)</td>
<td>-0.29 (-1.22, 0.98)</td>
<td>-0.23 (-0.97, 0.54)</td>
</tr>
<tr>
<td>ω-3 PUFA(^4) (%) (tissue)</td>
<td>0.42 (0.07, 0.73)</td>
<td>0.48 (0.17, 0.76)</td>
<td>0.44 (0.22, 0.66)</td>
</tr>
<tr>
<td>ω-3/ω-6 ratio (tissue)</td>
<td>0.01 (0.001, 0.02)</td>
<td>0.01 (0.006, 0.03)</td>
<td>0.01 (0.007, 0.02)</td>
</tr>
<tr>
<td>ω-6 PUFA(^4) (%) (diet)</td>
<td>-0.20 (-0.91, 0.62)</td>
<td>-1.81 (-2.50, -1.15)</td>
<td>-1.04 (-0.54, -1.54)</td>
</tr>
<tr>
<td>ω-3 PUFA(^4) (%) (diet)</td>
<td>0.11 (0.005, 0.24)</td>
<td>0.07 (-0.11, 0.26)</td>
<td>0.08 (-0.007, 0.20)</td>
</tr>
<tr>
<td>ω-3/ω-6 ratio (diet)</td>
<td>0.02 (0.004, 0.03)</td>
<td>0.05 (0.02, 0.09)</td>
<td>0.03 (0.02, 0.05)</td>
</tr>
<tr>
<td>ω-6 PUFA(^4) (%) (serum)</td>
<td>-0.13 (-1.26, 1.01)</td>
<td>-1.73 (-2.92, -0.41)</td>
<td>-1.04 (-1.73, -0.25)</td>
</tr>
<tr>
<td>ω-3 PUFA(^4) (%) (serum)</td>
<td>0.26 (0.02, 0.67)</td>
<td>0.34 (-0.06, 0.71)</td>
<td>0.32 (0.10, 0.57)</td>
</tr>
<tr>
<td>ω-3/ω-6 ratio (serum)</td>
<td>0.01 (-0.001, 0.02)</td>
<td>0.01 (0.002, 0.02)</td>
<td>0.01 (0.003, 0.02)</td>
</tr>
</tbody>
</table>

\(^1\)Values are the change in mean percentages for each fatty acid.
\(^2\)95% confidence intervals calculated with Wilcoxon signed rank test.
\(^3\)Monounsaturated fatty acid (MUFA)
\(^4\)Polyunsaturated fatty acid (PUFA)

Bolded values are significant with P-value<0.05.
Table 3. Linear regression modeling of colonic mucosal variables (\(\omega-3/\omega-6\) fatty acid ratios, PGE\(_2\) concentration in colon, cyclooxygenase (COX)-1 and 2 gene expression in colon) at 6 months as a factor of log change in Akkermansia abundance levels in all 86 individuals after dietary intervention adjusting for baseline colonic mucosal variable values. The data shown is the adjusted \(\beta\) regression coefficient and 95% confidence interval (CI). The adjusted \(R^2\) represents the fraction of variability in the colonic mucosal variable at 6 months that is explained by the linear regression model\(^1\).

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Change in (\omega-3) PUFA/(\omega-6) PUFA (^2)</th>
<th>Change in PGE2</th>
<th>Change in COX-1</th>
<th>Change in COX-2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adjusted (R^2=0.56)</td>
<td>Adjusted (R^2=0.58)</td>
<td>Adjusted (R^2=0.22)</td>
<td>Adjusted (R^2=0.22)</td>
</tr>
<tr>
<td>Overall model</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tissue (n-3) PUFA/(n-6) PUFA (baseline)</td>
<td>0.70 (0.56, 0.84)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tissue PGE2 (baseline)</td>
<td></td>
<td>0.81 (0.63, 1.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tissue COX-1 (baseline)</td>
<td></td>
<td></td>
<td>0.75 (0.54, 1.0)</td>
<td></td>
</tr>
<tr>
<td>Tissue COX-2 (baseline)</td>
<td></td>
<td></td>
<td></td>
<td>0.77 (0.57, 1.0)</td>
</tr>
<tr>
<td>Akkermansia (log change)</td>
<td>0.13 (0.02, 0.24)</td>
<td>-37 (-66, -6.8)</td>
<td>1.6 (-3.9, 0.64)</td>
<td>-0.19 (0.73, 0.35)</td>
</tr>
<tr>
<td>Dietary (n-3) PUFA/(n-6) PUFA (after dietary intervention)</td>
<td>-0.01(-0.10, 0.07)</td>
<td>5.6 (-17, 28)</td>
<td>-1.2 (-2.9, 0.54)</td>
<td>0.32 (-0.19, 0.83)</td>
</tr>
</tbody>
</table>

\(^1\) Multivariate linear regression with colonic mucosal variable at 6 months as the dependent variable adjusting for baseline colonic mucosal variable value, log change in Akkermansia, dietary colonic \(\omega-3/\omega-6\) PUFA at baseline, age, sex, and BMI. Bolded values are significant in the model with \(P\)-value<0.05

\(^2\) Abbreviations used are: polyunsaturated fatty acids (PUFA), Prostaglandin E2 (PGE2), Cyclooxygenase-1 (COX-1), Cyclooxygenase-2 (COX-2).
Figure 1. Alpha diversity, accessed by Shannon Index, across tertiles of A) dietary, B) serum and C) colonic mucosal ω-3/ω-6 PUFA levels after 6 months of dietary intervention.
Figure 2. Between microbial community differences across tertiles of A) dietary, B) serum and C) colonic mucosal ω-3/ω-6 PUFA levels following dietary intervention. The circles represent the different tertiles of ω-3/ω-6 PUFA ratios in diet, serum and colon biopsies. Non-metric multidimensional scaling (NMDS).

A) p-value = 1.00

B) p-value = 0.00

C) p-value = 0.46
Figure 3. Correlation between taxon abundance and dietary, serum and colonic mucosal ω-3/ω-6 PUFA ratios before and after 6 months of dietary intervention.